CMPX Valuation

Compass Therapeutics Inc.

Add to Watchlist

Advanced Chart

2.870

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

CMPX Relative Valuation

CMPX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CMPX is overvalued; if below, it's undervalued.

Historical Valuation

Compass Therapeutics Inc. (CMPX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.12. The fair price of Compass Therapeutics Inc. (CMPX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.87

Fair

-5.30

Trailing

Forward

-4.23

EV/EBITDA

Compass Therapeutics Inc.. (CMPX) has a current EV/EBITDA of -4.23. The 5-year average EV/EBITDA is -3.05. The thresholds are as follows: Strongly Undervalued below -8.18, Undervalued between -8.18 and -5.61, Fairly Valued between -0.49 and -5.61, Overvalued between -0.49 and 2.08, and Strongly Overvalued above 2.08. The current Forward EV/EBITDA of -4.23 falls within the Historic Trend Line -Fairly Valued range.

-4.88

EV/EBIT

Compass Therapeutics Inc.. (CMPX) has a current EV/EBIT of -4.88. The 5-year average EV/EBIT is -3.39. The thresholds are as follows: Strongly Undervalued below -8.66, Undervalued between -8.66 and -6.02, Fairly Valued between -0.75 and -6.02, Overvalued between -0.75 and 1.88, and Strongly Overvalued above 1.88. The current Forward EV/EBIT of -4.88 falls within the Historic Trend Line -Fairly Valued range.

0.00

Compass Therapeutics Inc.. (CMPX) has a current PS of 0.00. The 5-year average PS is 32.26. The thresholds are as follows: Strongly Undervalued below -192.73, Undervalued between -192.73 and -80.24, Fairly Valued between 144.75 and -80.24, Overvalued between 144.75 and 257.24, and Strongly Overvalued above 257.24. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-6.28

P/OCF

Compass Therapeutics Inc.. (CMPX) has a current P/OCF of -6.28. The 5-year average P/OCF is -5.76. The thresholds are as follows: Strongly Undervalued below -13.63, Undervalued between -13.63 and -9.69, Fairly Valued between -1.83 and -9.69, Overvalued between -1.83 and 2.11, and Strongly Overvalued above 2.11. The current Forward P/OCF of -6.28 falls within the Historic Trend Line -Fairly Valued range.

-7.18

P/FCF

Compass Therapeutics Inc.. (CMPX) has a current P/FCF of -7.18. The 5-year average P/FCF is -4.59. The thresholds are as follows: Strongly Undervalued below -13.95, Undervalued between -13.95 and -9.27, Fairly Valued between 0.09 and -9.27, Overvalued between 0.09 and 4.77, and Strongly Overvalued above 4.77. The current Forward P/FCF of -7.18 falls within the Historic Trend Line -Fairly Valued range.

Compass Therapeutics Inc. (CMPX) has a current Price-to-Book (P/B) ratio of 4.41. Compared to its 3-year average P/B ratio of 2.12 , the current P/B ratio is approximately 107.60% higher. Relative to its 5-year average P/B ratio of 3.01, the current P/B ratio is about 46.39% higher. Compass Therapeutics Inc. (CMPX) has a Forward Free Cash Flow (FCF) yield of approximately -8.89%. Compared to its 3-year average FCF yield of -15.21%, the current FCF yield is approximately -41.54% lower. Relative to its 5-year average FCF yield of -13.70% , the current FCF yield is about -35.11% lower.

4.41

P/B

Median3y

2.12

Median5y

3.01

-8.89

FCF Yield

Median3y

-15.21

Median5y

-13.70

Competitors Valuation Multiple

The average P/S ratio for CMPX's competitors is 10.00, providing a benchmark for relative valuation. Compass Therapeutics Inc. Corp (CMPX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CMPX.O

Compass Therapeutics Inc.

Arcturus Therapeutics Holdings Inc

6.46

-43.24%

486.34M

Performance Decomposition

Market capitalization of CMPX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CMPX in the past 1 year is driven by Unknown.